Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: Relationship to molecular mechanisms of gemcitabine resistance and survival

Clinical Cancer Research

Volumn 12, Issue 8, 2006, Pages 2492-2497

  Sebastiani, Valeria ^a   Ricci, Francesca ^a   Rubio Viquiera, Belen ^b   Kulesza, Piotr ^b   Yeo, Charles J ^c   Hidalgo, Manuel ^b   Klein, Alison ^b   Laheru, Daniel ^b   Iacobuzio Donahue, Christine A ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYCYTIDINE KINASE; GEMCITABINE;

ADULT; AGE; AGED; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; FEMALE; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METHYLATION; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 33646407273     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2655     Document Type: Article

References (30)

1. Galmarini CM, Clarke ML, Jordheim L, et al. Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol 2004;4:8.
2. Mackey JR, Mani RS, Selner M, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998;58:4349-57.
3. Bouffard DY, Laliberte J, Momparler RL. Kinetic studies on 2′,2′-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol 1993;45:1857-61.
4. Neff T, Blau CA. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol 1996;24:1340-6.
5. Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 1999;85:1261-8.
6. El Rayes BF, Philip PA. A review of systemic therapy for advanced pancreatic cancer. Clin Adv Hematol Oncol 2003;1:430-4.
7. Bergman AM, Pinedo HM, Jongsma AP, et al. Decreased resistance to gemcitabine (2′,2′-difluorodeoxycytidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase. Biochem Pharmacol 1999;57:397-406.
8. Chakravarthy A, Abrams RA, Yeo CJ, et al. Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. Int J Radiat Oncol Biol Phys 2000;48:1089-96.
9. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22:3776-83.
10. Obata T, Endo Y, Tanaka M, Uchida H, Matsuda A, Sasaki T. Deletion mutants of human deoxycytidine kinase mRNA in cells resistant to antitumor cytosine nucleosides. Jpn J Cancer Res 2001;92:793-8.
11. Stegmann AP, Honders MW, Hagemeijer A, Hoebee B, Willemze R, Landegent JE. In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2′-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene. Ann Hematol 1995;71:41-7.
12. Owens JK, Shewach DS, Ullman B, et al. Resistance to 1-β-D- arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res 1992;52:2389-93.
13. Flasshove M, Strumberg D, Ayscue L, et al. Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. Leukemia 1994;8:780-5.
14. Kroep JR, Loves WJ, van der Wilt CL, et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 2002;1:371-6.
15. Van Moorsel CJ, Veerman G, Ruiz v H, et al. Differential effects of gemcitabine on nucleotide pools of 19 solid tumor cell lines. Adv Exp Med Biol 1998;431:661-5.
16. Embuscado EE, Laheru D, Ricci F, et al. Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther 2005;4:548-54.
17. Jaffee EM, Schutte M, Gossett J, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am 1998;4:194-203.
18. Hatzis P, Al Madhoon AS, Jullig M, Petrakis TG, Eriksson S, Talianidis I. The intracellular localization of deoxycytidine kinase. J Biol Chem 1998;273:30239-43.
19. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
20. Jemal A, Murray T, Ward E, et al. Cancer statistics. CA Cancer J Clin 2005;55:10-30.
21. van der Wilt CL, Kroep JR, Loves WJ, et al. Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver. Eur J Cancer 2003;39:691-7.
22. Hubeek I, Peters GJ, Broekhuizen AJ, et al. Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours. J Clin Pathol 2005;58:695-9.
23. Veuger MJ, Honders MW, Willemze R, et al. Deoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemia. Eur J Haematol 2002;69:171-8.
24. Matsubayashi H, Sato N, Brune K, et al. Age- and disease-related methylation of multiple genes in non-neoplastic duodenum and in duodenal juice. Clin Cancer Res 2005;11:573-83.
25. Leegwater PA, De Abreu RA, Albertioni F. Analysis of DNA methylation of the 5′ region of the deoxycytidine kinase gene in CCRF-CEM-sensitive and cladribine (CdA)- and 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine (CAFdA)-resistant cells. Cancer Lett 1998;130:169-73.
26. Kong XB, Tong WP, Chou TC. Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine. Mol Pharmacol 1991;39:250-7.
27. Ruiz vHV, Veerman G, Eriksson S, Stegmann AP, Peters GJ. Induction of resistance to 2′,2′-difluorodeoxycytidine in the human ovarian cancer cell line A2780. Semin Oncol 1995;22:35-41.
28. Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res 2003;9:5000-8.
29. Rauchwerger DR, Firby PS, Hedley DW, Moore MJ. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res 2000;60:6075-9.
30. Spratlin J, Sangha R, Glubrecht D, et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 2004;10:6956-61.